| 2024-10-29 | +21.3% | earnings | Seeking Alpha | AtriCure Non-GAAP EPS of -$0.17 beats by $0.03, revenue of $115.91M beats by $3.66M |
| 2024-10-29 | +21.3% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-04-30 | -16.2% | earnings | Seeking Alpha | AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management |
| 2025-04-30 | -16.2% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript |
| 2024-10-30 | +15.0% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript |
| 2026-02-11 | -14.4% | analyst | Seeking Alpha | AtriCure slides 15% after JPMorgan downgrades over Edwards competition |
| 2026-01-14 | +14.1% | news | Seeking Alpha | AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2022-01-10 | +13.7% | legal | SEC EDGAR | ATRC 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-12 | -12.2% | legal | SEC EDGAR | ATRC 8-K: 1.01, 2.02, 2.03 (SEC Filing) |
| 2025-04-29 | -11.8% | earnings | Seeking Alpha | AtriCure Non-GAAP EPS of -$0.14 beats by $0.08, revenue of $123.62M beats by $0.7M |
| 2025-04-29 | -11.8% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-07-30 | +11.1% | news | simplywall.st | Numerous AtriCure Insiders Sold Stock: Not A Positive Omen - simplywall.st |
| 2025-01-13 | +10.1% | news | Seeking Alpha | AtriCure reports preliminary results for fourth quarter |
| 2025-01-13 | +10.1% | legal | SEC EDGAR | ATRC 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-02 | +8.9% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2021-11-03 | +8.9% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2024-05-01 | -8.5% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2024-07-25 | -8.5% | news | Seeking Alpha | AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care |
| 2023-01-09 | -8.0% | legal | SEC EDGAR | ATRC 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-07-25 | +7.9% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2023-02-21 | +7.4% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-07-29 | +6.1% | earnings | Seeking Alpha | AtriCure raises 2025 revenue outlook to $527M-$533M with strong Q2 growth and innovation milestones |
| 2025-07-29 | +6.1% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript |
| 2025-07-29 | +6.1% | earnings | Seeking Alpha | AtriCure Non-GAAP EPS of -$0.02 beats by $0.14, revenue of $136.1M beats by $5.84M |
| 2025-07-29 | +6.1% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2022-05-03 | -6.1% | legal | SEC EDGAR | ATRC 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-04-27 | +5.9% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | +5.6% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | AtriCure (ATRC) Quarter End | Q4 2025: EPS Exceeds Expectations - Expert Verified Trades - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-10-29 | -5.4% | earnings | Seeking Alpha | AtriCure Non-GAAP EPS of -$0.01 beats by $0.11, revenue of $134.27M beats by $3.02M |
| 2025-10-29 | -5.4% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-02-12 | -5.4% | earnings | Seeking Alpha | AtriCure GAAP EPS of -$0.33 misses by $0.09, revenue of $124.28M beats by $2.44M |
| 2025-02-12 | -5.4% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-05-20 | +4.7% | legal | SEC EDGAR | ATRC 8-K: 5.02, 5.07 (SEC Filing) |
| 2024-07-31 | -4.5% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript |
| 2025-02-13 | -4.4% | earnings | Seeking Alpha | AtriCure targets $517M-$527M revenue in 2025 with new product launches and international growth |
| 2025-02-13 | -4.4% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript |
| 2026-04-21 | -4.4% | earnings | MarketBeat | AtriCure (NASDAQ:ATRC) Sets New 52-Week Low - Here's Why - MarketBeat |
| 2023-05-26 | -4.2% | legal | SEC EDGAR | ATRC 8-K: 5.02 and 5.07 (SEC Filing) |
| 2022-02-15 | +4.1% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-04-08 | -4.0% | news | Seeking Alpha | AtriCure Drops 25%: Bargain Or Caution Sign? |
| 2022-05-27 | -3.6% | legal | SEC EDGAR | ATRC 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-02-24 | -3.5% | news | Business Wire | AtriCure to Participate in the Citizens Life Sciences Conference |
| 2024-05-14 | -3.3% | legal | SEC EDGAR | ATRC 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2024-07-23 | +3.1% | legal | Seeking Alpha | AtriCure receives regulatory approval to sell AtriClip devices in China |
| 2026-04-18 | -2.9% | earnings | MarketBeat | Oak Harvest Investment Services Makes New $1.48 Million Investment in AtriCure, Inc. $ATRC - MarketBeat |
| 2024-07-30 | -2.9% | earnings | Seeking Alpha | AtriCure Non-GAAP EPS of -$0.17 in-line, revenue of $116.3M beats by $0.12M |
| 2024-07-30 | -2.9% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2026-03-11 | +2.9% | executive | MarketBeat | AtriCure CFO Sees 12%-14% Organic Growth in 2026 as Pain Management Adoption Accelerates |
| 2026-03-25 | +2.7% | news | Zacks | AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains? |
| 2023-11-01 | +2.6% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2021-08-04 | -2.6% | legal | SEC EDGAR | ATRC 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-02-27 | +2.4% | legal | SEC EDGAR | ATRC 8-K: 5.02 and (SEC Filing) |
| 2025-11-29 | -2.4% | news | The Motley Fool | Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares? - The Motley Fool |
| 2024-01-08 | +2.1% | legal | SEC EDGAR | ATRC 8-K: 1.01, 1.02, 2.02, 2.03 (SEC Filing) |
| 2026-02-18 | -2.0% | earnings | Seeking Alpha | AtriCure targets 12%-14% revenue growth in 2026 as innovation and clinical progress drive momentum |
| 2026-02-18 | -2.0% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript |
| 2026-02-18 | -2.0% | news | TradingView | Reasons to Hold HealthEquity Stock in Your Portfolio for Now - TradingView |
| 2026-02-17 | -1.9% | earnings | Seeking Alpha | AtriCure Non-GAAP EPS of $0.06 beats by $0.10, revenue of $140.5M beats by $0.72M |
| 2026-02-17 | -1.9% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2026-02-17 | -1.9% | earnings | Yahoo Finance | AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance |
| 2026-03-28 | -1.8% | news | Xã Thanh Hà | Is AtriCure (ATRC) Stock in consolidation phase | Price at $28.43, Up 0.71% - Market Analysis - Xã Thanh Hà |
| 2024-01-04 | -1.8% | legal | SEC EDGAR | ATRC 8-K: 5.02 and (SEC Filing) |
| 2025-10-30 | -1.7% | earnings | Seeking Alpha | AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth |
| 2025-10-30 | -1.7% | earnings | Seeking Alpha | AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript |
| 2026-02-20 | -1.5% | news | Kalkine Media | Is AtriCure (NASDAQ:ATRC) Facing New Pressure In The Nasdaq Index? - Kalkine Media |
| 2026-03-02 | +1.5% | earnings | Simply Wall St. | Will AtriCure’s (ATRC) 2026 Profitability Guidance Mark a Turning Point in Its Investment Narrative? |
| 2022-11-01 | -1.3% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2025-06-26 | -1.3% | earnings | Seeking Alpha | AtriCure: Profits And Operating Leverage Are Needed Here |
| 2026-04-06 | -1.1% | executive | Moomoo | AtriCure, Inc. ($ATRC) CEO 2025 Pay Revealed - Moomoo |
| 2026-04-01 | +1.0% | analyst | Investing.com | Freedom Capital Markets initiates Articure stock with buy rating - Investing.com |
| 2026-03-22 | +1.0% | earnings | Motley Fool | This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth |
| 2026-03-22 | +1.0% | news | Motley Fool | This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash |
| 2026-03-21 | +1.0% | legal | Motley Fool | DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing |
| 2025-11-10 | +0.7% | news | Seeking Alpha | AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript |
| 2025-10-31 | -0.7% | earnings | Seeking Alpha | AtriCure, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-07-08 | +0.7% | earnings | simplywall.st | AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry? - simplywall.st |
| 2026-02-19 | +0.5% | legal | TradingView | AtriCure, Inc. SEC 10-K Report - TradingView |
| 2021-06-15 | -0.5% | legal | SEC EDGAR | ATRC 8-K: 5.02 and (SEC Filing) |
| 2026-04-09 | -0.5% | news | Simply Wall St. | Assessing AtriCure (ATRC) Valuation After Prolonged Share Price Weakness |
| 2026-04-09 | -0.5% | earnings | MarketBeat | AtriCure (NASDAQ:ATRC) Reaches New 12-Month Low - Time to Sell? - MarketBeat |
| 2026-04-14 | +0.5% | news | Business Wire | AtriCure to Announce First Quarter 2026 Financial Results |
| 2026-01-19 | +0.4% | news | Seeking Alpha | AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2026-03-03 | +0.4% | news | Stock Titan | AtriCure (ATRC) CLO receives stock awards and surrenders shares for taxes - Stock Titan |
| 2024-02-15 | +0.4% | legal | SEC EDGAR | ATRC 8-K: 2.02 and (SEC Filing) |
| 2026-03-18 | -0.2% | news | Motley Fool | AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? |
| 2022-08-02 | +0.2% | legal | SEC EDGAR | ATRC 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-05 | -0.1% | earnings | MarketBeat | AtriCure (NASDAQ:ATRC) Raised to Strong-Buy at Wall Street Zen - MarketBeat |
| 2024-07-29 | -0.0% | earnings | Seeking Alpha | AtriCure Q2 2024 Earnings Preview |
| 2026-04-24 | — | news | MEXC Exchange | ATRC Price Today: AtriCure, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange |